Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma
NCT05018299
Asthma, Bronchial Diseases
Kaohsiung City, Taiwan
View Trial DetailsNCT Number: NCT03065920
This study is a prospective observational multicentre cohort study of asthma patients in Eastern Africa whose objectives will be; The primary objective of this project is to identify and characterize severe asthma in Eastern Africa in order to understand its demographic, clinical, physiologic, pathologic, genomic and immunologic determinants.
Secondary objective(s) are; Compare the annual healthcare utilisation (HCU) (emergency room visits, hospitalization including admission to critical care units and unscheduled outpatient clinic or office visits), exacerbation, quality of life and mortality rates of severe and not- severe asthma patients Determine the factors associated with the asthma HCU events, quality of life, exacerbations and mortality The study will enroll 1676 patients aged between 12 and 70 years and follow up each patient for up to one year.
Looking for future studies?
Notify Me12 year–70 year
All sexes
Observational
Black Lion Hospital, Addis Ababa, Central, Ethiopia
This study is a prospective observational multicentre cohort study of asthma patients in Eastern Africa. whose objectives will be; The primary objective of this project is to identify and characterize severe asthma in Eastern Africa in order to understand its demographic, clinical, physiologic, pathologic, genomic and immunologic determinants.
Secondary objective(s) are; Compare the annual healthcare utilisation (HCU) (emergency room visits, hospitalization including admission to critical care units and unscheduled outpatient clinic or office visits), exacerbation, quality of life and mortality rates of severe and not- severe asthma patients Determine the factors associated with the asthma HCU events, quality of life, exacerbations and mortality.
The study will enroll 1676 patients aged between 12 and 70 years and follow up each patient for up to one year.
Measurements; The following will be done
Further measurements to characterise asthma will be performed and include;
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
In addition the following patients will be excluded:
Time frame: 3 years
The primary end point in this study is severe asthma. We shall document the proportion of the enrolled patients that have severe asthma and perform a factor analysis to identify factors independently associated with severe asthma.
Time frame: 3 years
Incidences rates of this outcome between groups (severe and not severe asthma) will be compared and predictors of this outcome analysed.
Time frame: 3 years
Incidences rates of this outcome between groups (severe and not severe asthma) will be compared and predictors of this outcome analysed.
Time frame: 3 years
Incidences rates of this outcome between groups (severe and not severe asthma) will be compared and predictors of this outcome analysed.
Time frame: 3 years
Incidences rates of this outcome between groups (severe and not severe asthma) will be compared and predictors of this outcome analysed.
Makerere University
Other
African Severe Asthma Program
Acronym: ASAP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05018299
Asthma, Bronchial Diseases
Kaohsiung City, Taiwan
View Trial DetailsNCT06666504
Asthma, Bronchial Diseases
London, United Kingdom
View Trial DetailsNCT04680117
Asthma, Bronchial Diseases
Paris, France
View Trial DetailsNCT06196879
Asthma, Bronchial Diseases
Birmingham, Alabama, United States
View Trial Details